The combined use of aspirin, a statin, and blood pressure-lowering agents (polypill components) and the risk of vascular morbidity and mortality in patients with coronary artery disease

American Heart Journal

Volumn 166, Issue 2, 2013, Pages

  Lafeber, Melvin ^a   Spiering, Wilko ^a   Van Der Graaf, Yolanda ^a   Nathoe, Hendrik ^a   Bots, Michiel L ^a   Grobbee, Diederick E ^a   Visseren, Frank L J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIAC PATIENT; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; COHORT ANALYSIS; CORONARY ARTERY DISEASE; FEMALE; FOLLOW UP; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; OBSERVATIONAL STUDY; PRESCRIPTION; PRIORITY JOURNAL; PROPENSITY SCORE;

EID: 84880919203     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2013.04.011     Document Type: Article

References (25)

1. C. Baigent, L. Blackwell, and R. Collins Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials Lancet 373 2009 1849 1860
2. C. Baigent, L. Blackwell, and J. Emberson Efficacy and safety of more intensive lowering of ldl cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 2010 1670 1681
3. M.R. Law, J.K. Morris, and N.J. Wald Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies BMJ 338 2009 b1665
4. I. Graham, D. Atar, and K. Borch-Johnsen European guidelines on cardiovascular disease prevention in clinical practice: executive summary Eur Heart J 28 2007 2375 2414
5. R. Jackson, C.M. Lawes, and D.A. Bennett Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk Lancet 365 2005 434 441 (Pubitemid 40179232)
6. Jbs 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice Heart 91 Suppl. 5 2005 v1 v52
7. K. Kotseva, D. Wood, and G. De Backer Cardiovascular prevention guidelines in daily practice: a comparison of Euroaspire I, II, and III surveys in eight European countries Lancet 373 2009 929 940
8. S. Yusuf, S. Islam, and C.K. Chow Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the pure study): a prospective epidemiological survey Lancet 378 9798 2011 1231 1243
9. L.K. Newby, N.M. LaPointe, and A.Y. Chen Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease Circulation 113 2006 203 212
10. A.J. Claxton, J. Cramer, and C. Pierce A systematic review of the associations between dose regimens and medication compliance Clin Ther 23 2001 1296 1310 (Pubitemid 32804122)
11. C.I. Coleman, M.S. Roberts, and D.M. Sobieraj Effect of dosing frequency on chronic cardiovascular disease medication adherence Curr Med Res Opin 28 5 2012 669 680
12. M. Lafeber, W. Spiering, and K. Singh The cardiovascular polypill in high-risk patients Eur J Prev Cardiol 19 6 2012 1234 1242
13. S. Yusuf, P. Pais, and R. Afzal Effects of a polypill (polycap) on risk factors in middle-aged individuals without cardiovascular disease (tips): a phase II, double-blind, randomised trial Lancet 373 2009 1341 1351
14. F. Malekzadeh, T. Marshall, and A. Pourshams A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy ('polypill') on cardiovascular risk factors Int J Clin Pract 64 2010 1220 1227
15. A. Rodgers, A. Patel, and O. Berwanger An international randomised placebo-controlled trial of a four-component combination pill ("polypill") in people with raised cardiovascular risk PLoS One 6 2011 e19857
16. P.C. Simons, A. Algra, and M.F. van de Laak Second manifestations of arterial disease (smart) study: rationale and design Eur J Epidemiol 15 1999 773 781
17. A.R. Donders, G.J. van der Heijden, and T. Stijnen Review: a gentle introduction to imputation of missing values J Clin Epidemiol 59 2006 1087 1091 (Pubitemid 44374314)
18. P.R. Rosenbaum, and D.B. Rubin The central role of the propensity score in observational studies for causal effects Biometrika 70 1983 41 55
19. M. Umbrello, G. Mistraletti, and D. Corbella Bias reduction in repeated-measures observational studies by the use of propensity score: the case of enteral sedation for critically ill patients J Crit Care 27 6 2012 662 672
20. M.R. Law, H.C. Watt, and N.J. Wald The underlying risk of death after myocardial infarction in the absence of treatment Arch Intern Med 162 2002 2405 2410 (Pubitemid 35340454)
21. K. Hardie, K. Jamrozik, and G.J. Hankey Trends in five-year survival and risk of recurrent stroke after first-ever stroke in the Perth Community Stroke Study Cerebrovasc Dis 19 2005 179 185 (Pubitemid 40754336)
22. S. Wells, J. Broad, and R. Jackson Estimated prevalence of cardiovascular disease and distribution of cardiovascular risk in New Zealanders: data for healthcare planners, funders, and providers N Z Med J 119 2006 U1935
23. Thompson AM, Hu T, Eshelbrenner CL, et al. Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: A meta-analysis. JAMA. 305:913-922
24. U. Zeymer, C. Junger, and R. Zahn Effects of a secondary prevention combination therapy with an aspirin, an ace inhibitor and a statin on 1-year mortality of patients with acute myocardial infarction treated with a beta-blocker. Support for a polypill approach Curr Med Res Opin 27 2011 1563 1570
25. R.B. D'Agostino Jr. Statistical primer for cardiovascular research; propensity scores in cardiovascular research Circulation 115 2007 2340 2343